Drugs / CIGB300
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01639625 | May 2011 → Sep 2015 | cervical adenocarcinoma, cervical squamous cell carcinoma | Laboratorio Elea Phoenix S.A. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01639638 | Jun 2010 → Dec 2012 | anogenital human papillomavirus infection | Laboratorio Elea Phoenix S.A. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CIGB300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01639625 ↗ |
| Modality | Peptide | “PROAPOPTOTIC PEPTIDE CIGB 300” NCT01639638 ↗ |
| Route | Other | “for local application” NCT01639625 ↗ |